Novartis Leqvio ® (inclisiran) FDA Approved Cholesterol-Lowering Medication

Dr. Norman Lepor, cardiologist and a clinical investigator in the Phase III clinical program for Leqvio ®  (inclisiran), discusses the recent FDA approval of Leqvio,  a first-in-class siRNA to lower bad cholesterol  and keep it low with  two doses a year, after an initial dose and one at three months. Leqvio is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. 

Dr. Norman Lepor is a Los Angeles based cardiologist and a clinical investigator in the Phase III clinical program for Leqvio. Throughout Dr. Lepor’s career, he has focused on the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). He also specializes in the treatment of cholesterol disorders, hypertension, heart failure, and diabetic heart disease, among other types of cardiovascular disease (CVD), and has performed more than 6,000 heart procedures. In addition, Dr. Lepor has been a clinical investigator in several pivotal clinical trials of investigational treatments for ASCVD with over 60 peer reviewed medical publications.

Dr. Lepor is a fellow of the American College of Cardiology and past president of the California chapter of the American College of Cardiology. He is board certified in internal medicine and cardiovascular diseases by the American Board of Internal Medicine and completed his medical education at The Johns Hopkins University School of Medicine with post-doctoral training in cardiology at Cedars-Sinai Medical Center.